Stock Groups

BioMarin Surges as FDA Oks Injection for Improving Growth in Children -Breaking

by Mike Robinson

[ad_1]


By Dhirendra Tripathi

Investing.com – Biomarin stock (NASDAQ:) soared 8% Friday as a U.S. regulator approved the company’s injection aimed at improving growth in children suffering from achondroplasia.

Achondroplasia refers to a rare form of short stature that is caused by a genetic condition that causes bone loss.

The FDA has approved the drug, but the company must still conduct post-marketing studies.

Voxzogo is a drug developed by BioMarin. It works by inhibiting the activity of a gene which prevents normal bone development in people with this disorder.

In August, the European Commission approved the drug. This makes it the first treatment for achondroplasia. The company stated that marketing authorizations are currently being reviewed in Japan, Brazil and Australia, with the possibility of approvals for these countries by 2022.

BioMarin stated that Voxzogo will be made available in the U.S.A by December 31st.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]